Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Marksans-Pharma"

37 News Found

Marksans Pharma gets USFDA approval for Esomeprazole Magnesium delayed-release capsules
Drug Approval | October 05, 2023

Marksans Pharma gets USFDA approval for Esomeprazole Magnesium delayed-release capsules

This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals


Marksans Pharma completes acquisition of manufacturing site from Tevapharm India
News | April 20, 2023

Marksans Pharma completes acquisition of manufacturing site from Tevapharm India

Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards


Marksans Pharma announces USFDA approval for Famotidine Tablets
News | March 11, 2023

Marksans Pharma announces USFDA approval for Famotidine Tablets

Marksans' OTC Famotidine Tablets USP are acid reducers


Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution
News | January 24, 2023

Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK


Marksans Pharma raises Rs. 372.40 crores
News | January 21, 2023

Marksans Pharma raises Rs. 372.40 crores

OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.


Marksans Pharma posts Q1FY23consolidated PAT at Rs. 59.71 Cr
News | August 16, 2022

Marksans Pharma posts Q1FY23consolidated PAT at Rs. 59.71 Cr

The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.


Briefs: Marksans Pharma and Alkem
News | June 22, 2022

Briefs: Marksans Pharma and Alkem

The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.


Marksans Pharma Q3FY22 PAT at Rs. 48.27 crore
News | February 11, 2022

Marksans Pharma Q3FY22 PAT at Rs. 48.27 crore

Marksans Pharma has reported consolidated financial results for the period ended December 31, 2021


Marksans Pharma shareholders vote for warrants worth Rs. 365 Cr
News | July 11, 2021

Marksans Pharma shareholders vote for warrants worth Rs. 365 Cr

The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant


Marksans Pharma Q4 FY21 profit up 86%
News | June 01, 2021

Marksans Pharma Q4 FY21 profit up 86%

The company's operating revenue for Q4 FY21 was Rs. 330.2 crore